Navigation Links
AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell
Date:12/4/2009

ctice was initiated in October 2009 in the UK, following EU approval.

The course is a peer-reviewed publication titled "Advances in Orthodontic Treatment," and was authored by Jeremy J. Mao, DDS, PhD, who recently lectured internationally on the biological action of pulsatile force, and Chung H. Kau, DDS, MScD, MBA, PhD, MOrth, FDS, FFD (Ortho), FAMS (Ortho), who oversaw the Phase I clinical trial that featured the first use of the AcceleDent technology in patients at the University of Texas Dental Branch. The course is intended for orthodontists and dental professionals and awards 4 CE credits. PennWell is an ADA CERP (Continuing Education Recognition Program) provider.

Dr. Jeremy Mao observed, "We believe that a great deal of knowledge has been unveiled in recent years as it relates to pulsatile forces and biological response of alveolar bone. The scientific data have important implications in the rate of orthodontic treatment. This course is a timely opportunity to create awareness around these concepts." He continued, "The Phase I clinical trial conducted at the University of Texas Dental Branch represents scientific validation of years of animal data on the effectiveness of pulsatile forces." Brent Tarver, VP Clinical Affairs for the Company added, "OrthoAccel is committed to its investment in a clinical strategy that is ultimately intended to not only elaborate the scientific basis for AcceleDent, but also discover new ways to improve orthodontic care."

OrthoAccel is presently controlling availability of AcceleDent in the UK to
'/>"/>

SOURCE OrthoAccel Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
2. Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers
3. Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
4. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
5. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
6. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
7. Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors
8. Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research
9. Derma Sciences Files S-1 Registration Statement
10. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
11. Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANCISCO , Aug. 27, 2015  QB3@953—a ... by QB3, a University of California (UC) research ... with pharmaceutical company GSK to identify and facilitate ... medicines that benefit patients. The agreement ... Partnerships with Academia (DPAc) team and creates a ...
(Date:8/27/2015)... CAMBRIDGE, Mass. , Aug. 27, 2015 /PRNewswire/ ... the Rodman & Renshaw 17th Annual Global Investment Conference in ... St. Regis Hotel, ORYZON will be represented by President and ... Dr. Buesa will present this information on ... Fontainebleau Room (2nd Floor).  The company is completing preclinical development ...
(Date:8/26/2015)... August 27, 2015 ... the genotyping technology, its application and products ... nucleotide polymorphism (SNP) genotyping industry analysis are ... report on genotyping market by technology, application ... profiling 10 major companies and supported with ...
Breaking Medicine Technology:QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 2Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 3Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 4Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 5
... , May 14 Medco Health Solutions, Inc., (NYSE: ... donated $125,000 to the U.S. Red Cross for relief efforts targeted ... , , , ... largest pharmacies and parent company of Memphis -based Accredo Health Group -- ...
... , May 14 Hospira, Inc. ... specialty pharmaceutical and medication delivery company, will expand its ... to its portfolio of non-DEHP intravenous (I.V.) administration sets. ... increased customer efficiency and reduced impact on the environment, ...
Cached Medicine Technology:Medco Donates $125,000 to Red Cross for Flood Relief in Tennessee and Other Affected Areas 2Medco Donates $125,000 to Red Cross for Flood Relief in Tennessee and Other Affected Areas 3Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 3Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 4
(Date:8/27/2015)... ... August 27, 2015 , ... In the addiction treatment industry, some patients ... later, relapsing and returning again, all at great cost to them and their families. ... homes or soon after leaving facilities who claim to have given addicts tools to ...
(Date:8/27/2015)... ... August 27, 2015 , ... In an article published July ... the city of New Orleans, highlighting a security firm that is tasked with providing ... tech oriented entrepreneur who worked with the city to provide private security when it ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent ... into the Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands ... Georgia State University study. , While most people don’t develop persistent depression after ...
(Date:8/27/2015)... ... , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., CEO of ... practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study and treatment ... in Healthpointe’s La Mirada clinic and Garden Grove clinic. , Acupuncture ...
(Date:8/27/2015)... and OKLAHOMA CITY, OK (PRWEB) , ... August ... ... Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing ... be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
Breaking Medicine News(10 mins):Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4
... , , BATESVILLE, ... and Radianse today announced a strategic partnership agreement to integrate ... Nurse Call system. With this move, Hill-Rom intends to ... to remove financial and technical obstacles for health care customers ...
... NOVATO, Calif., Sept. 2 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Financial Officer of BioMarin, will present a company update at the Thomas ... 4:25 p.m. ET. , , Interested parties ... investor section of the BioMarin website, www.BMRN.com . ...
... , SOMERSET, N.J., Sept. 2 ... US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine ... of seasonal and perennial allergic rhinitis (SAR and PAR). ... to offer convenient once-daily dosing for patients who suffer from ...
... BEIJING, Sept. 2 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; ... Xinhua News Agency publicized the creation of "Opinions of the,CPC ... of the,Medical and Health Care System" ("Opinion"). , ... to go see a,doctor more easily. Reduced cost is the ...
... , , , ... 2 /PRNewswire-FirstCall/ -- DUSA ... is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other products ... President and Chief Executive Officer, will present a corporate overview at ...
... , , SAN JOSE, Calif., ... device company, today announced that its IsoFlow (TM) ... and Drug Administration (FDA) for the direct delivery of medications into ... the treatment of cancer. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090902/SF69552 ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:BioMarin to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 2Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 3Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4
... ABI Prism 7000 Sequence Detection System ... that detects and quantitates nulceic acid ... of accumulated PCR product is made ... detection, and application-specific software in a ...
... system offers continuous, unattended operation with ... and detection, and data analysis. After ... importing sample information, the operator needs ... command. The instrument requires no further ...
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
RIA kit for the quantitative determination of autoantibodies to thyroglobulin in serum....
Medicine Products: